1 Amazing Chart Shows Why Gilead Sciences, Inc.'s Stock Still Belongs in Your Portfolio
Gilead Sciences saw its shares drop by close to 20% after its chief competitor, AbbVie, delivered a major blow to its hepatitis C franchise. A single chart, though, shows why selling this top biotech stock is probably a huge mistake.
Gilead Sciences, Inc. Fires Back at AbbVie Inc.
Gilead Sciences has cut a deal with CVS Health in response to AbbVie's Express Scripts agreement.
The Biggest Surprise in the Battle Between AbbVie and Gilead Sciences
AbbVie and Gilead Sciences continue their hep-C duel. Here's what is most surprising so far.